Daniel Patrick O’day Sells 10,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $126.54, for a total transaction of $1,265,400.00. Following the transaction, the chief executive officer directly owned 571,203 shares of the company’s stock, valued at $72,280,027.62. This represents a 1.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Daniel Patrick O’day also recently made the following trade(s):

• On Tuesday, October 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00.
• On Monday, September 29th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00.

Gilead Sciences Stock Down 0.3%

Shares of NASDAQ:GILD opened at $123.91 on Wednesday. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The stock has a fifty day simple moving average of $120.30 and a two-hundred day simple moving average of $115.02. Gilead Sciences, Inc. has a 12-month low of $88.57 and a 12-month high of $128.70. The stock has a market capitalization of $153.73 billion, a price-to-earnings ratio of 19.21, a PEG ratio of 0.69 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the firm posted $2.02 earnings per share. The company’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.6%. Gilead Sciences’s payout ratio is 48.99%.

Institutional Trading of Gilead Sciences

A number of hedge funds have recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $2,150,268,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after buying an additional 11,156,382 shares during the last quarter. Nuveen LLC bought a new stake in Gilead Sciences during the first quarter valued at approximately $620,415,000. Ameriprise Financial Inc. grew its position in Gilead Sciences by 397.6% during the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after buying an additional 5,392,191 shares during the period. Finally, Invesco Ltd. increased its holdings in Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after buying an additional 3,394,330 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on GILD shares. Wells Fargo & Company increased their price target on shares of Gilead Sciences from $140.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, October 31st. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Mizuho boosted their price target on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Morgan Stanley upped their price target on Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Finally, Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $130.65.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.